FDA Approves Medtronic's Leadless Pacemaker With Large Postmarket Trial Condition
This article was originally published in The Gray Sheet
As a condition of approval for the Micra pacer, Medtronic has agreed to conduct a post-approval study with at least 1,830 “real-world” patients, according to the company.
You may also be interested in...
No patient injuries related to the Nanostim issues have been reported, but it puts St. Jude further behind Medtronic and Boston Scientific in the emerging leadless pacemaker market. The company says the problem reported with seven Nanostim devices is not related to the lithium-deposit problem that recently caused batter depletion in some of its high voltage devices.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.